Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
Data from Phase 3 MANEUVER study demonstrating significant improvements in physical function and symptoms in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, to be featured in oral presentation Latest results for potential first-in-